Bank of Montreal Can reduced its stake in shares of Sanofi (NASDAQ:SNY – Free Report) by 0.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 233,086 shares of the company’s stock after selling 1,944 shares during the quarter. Bank of Montreal Can’s holdings in Sanofi were worth $11,713,000 at the end of the most recent quarter.
Other large investors have also recently added to or reduced their stakes in the company. Barrow Hanley Mewhinney & Strauss LLC increased its position in Sanofi by 113.8% in the 2nd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock valued at $288,381,000 after acquiring an additional 3,164,092 shares during the period. Magnetar Financial LLC raised its stake in shares of Sanofi by 1,153.1% during the second quarter. Magnetar Financial LLC now owns 2,506,286 shares of the company’s stock valued at $121,605,000 after purchasing an additional 2,306,286 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in Sanofi by 19.0% in the second quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock worth $417,017,000 after purchasing an additional 1,370,232 shares during the period. Mondrian Investment Partners LTD grew its position in Sanofi by 43.1% in the 1st quarter. Mondrian Investment Partners LTD now owns 3,951,089 shares of the company’s stock valued at $192,023,000 after buying an additional 1,190,141 shares in the last quarter. Finally, Armistice Capital LLC acquired a new position in Sanofi during the 4th quarter valued at about $51,520,000. 10.04% of the stock is owned by institutional investors and hedge funds.
Sanofi Price Performance
Shares of SNY opened at $57.65 on Monday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The firm has a market cap of $146.01 billion, a PE ratio of 28.97, a PEG ratio of 1.62 and a beta of 0.60. The firm’s 50 day moving average price is $55.04 and its 200 day moving average price is $50.84. Sanofi has a twelve month low of $42.63 and a twelve month high of $58.97.
Analysts Set New Price Targets
Several brokerages recently commented on SNY. StockNews.com raised Sanofi from a “buy” rating to a “strong-buy” rating in a report on Thursday. Argus boosted their price objective on Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Finally, Citigroup upgraded Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Three investment analysts have rated the stock with a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $57.50.
Check Out Our Latest Research Report on Sanofi
Sanofi Company Profile
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Recommended Stories
- Five stocks we like better than Sanofi
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Simon Property REIT: A Safe Bet for Growth and Steady Dividends
- How to Buy Cheap Stocks Step by Step
- CarMax’s Impressive Rally: What Investors Should Watch Next
- What is Insider Trading? What You Can Learn from Insider Trading
- MarketBeat Week in Review – 9/23 – 9/27
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY – Free Report).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.